Revolo Biotherapeutics Announces New Preclinical Data Further Validating Atopic Dermatitis as a Target Indication for ‘1104

Revolo Biotherapeutics notes the data reinforces the broad clinical applicability of ‘1104, through a novel upstream mechanism of action (MOA), demonstrating its impact across skin disease measures and a wide range of inflammatory cytokines and chemokines associated with AD pathology.